Latest for Day One Biopharmaceuticals

Highlight

Endpoints News: It’s a new $DAWN for Day One as startup pivots to an IPO for more funding to back its work in pediatric cancer

Pediatric cancer biotech Day One Pharmaceuticals is headed for Nasdaq, in a move that comes less than three months after their work on a brain...
Highlight

A milestone in targeted oncology and looking ahead

In honor of this historic event, we want to share a few thoughts about the future of targeted oncology and where we are making investments at Canaan.
Highlight

Fierce Biotech: Childhood cancer-focused Day One snags Gilead alum Bender for CEO

Day One Biopharmaceuticals emerged in May to develop new drugs specifically for children with cancer. Now, as it ramps up its work, the company is...
Highlight

Julie Grant: Cancer drug development comes of age - The inspiration behind Day One Biopharmaceuticals

The inspiration for Day One Biopharmaceuticals emerged from an inequity in patient care highlighted by leaders in the pediatric oncology community.
Highlight

STAT News: Startup Spotlight - Aiming to speed precision cancer therapies to children

Day One — named for the conversations clinicians have with parents when they first tell them their child has cancer and how they hope to treat it —...
Highlight

FierceBiotech: Day One debuts with $60M to change cancer care—starting with children

Day One is launching to develop new cancer treatments for children, but that could be used in adult patients, too.
Highlight

WSJ Pro VC: Cancer drugmaker Day One Biopharmaceuticals launches with $60 million

The startup aims to develop cancer treatments for children and adults.